Continuous glucose monitors, the small wearable sensors best known for helping people who use insulin, may benefit a much wider group of patients. The largest clinical trial of its kind, published in the New England Journal of Medicine, has found that adults with type 2 diabetes who do not use insulin spent approximately five more hours a day in their target blood sugar range when they used a continuous glucose monitor.
The result is significant because most people with type 2 diabetes are not on insulin and have traditionally relied on occasional finger-prick tests, which capture only a single moment rather than the full daily pattern of rises and falls.
What the Trial Found
Researchers reported that participants wearing the sensors could see, in real time, how meals, activity and medication affected their glucose levels. That feedback loop appears to be the mechanism behind the improvement: people adjusted what they ate, when they walked and how consistently they took medication, guided by trends they could actually observe.
A summary of the findings from the University of Colorado Anschutz Medical Campus notes the scale of the trial and the size of the effect, around five additional hours a day within the healthy target range. Time in range is increasingly regarded by clinicians as a meaningful measure, because it reflects stability through the day and night rather than a single averaged figure.
Why Time in Range Matters
Traditional monitoring centres on HbA1c, a blood test that gives an average over several months. Two patients can share the same average while experiencing very different daily swings, including unnoticed lows and prolonged highs after meals. Continuous monitors fill in those blind spots, recording readings every few minutes and revealing patterns that a quarterly test cannot show.
Spending more hours in range is associated with feeling better day to day and, over the long term, with a lower risk of the complications that make diabetes such a serious condition, including damage to eyes, kidneys and nerves. The trial therefore speaks to both quality of life now and health outcomes later.
The finding also connects with a broader theme in preventive health: small, well-timed feedback can change daily habits more effectively than occasional advice, much as we explored in our article on how morning exercise may sharpen memory, mood and focus.
Barriers Still Stand in the Way
Access remains the central question. In many health systems, continuous glucose monitors are funded mainly for people on intensive insulin therapy, and sensors and replacement patches carry ongoing costs. A trial result of this size strengthens the case for wider coverage, but payers will want to weigh the upfront expense against savings from avoided complications.
There are practical considerations too. Wearing a sensor requires comfort with a device on the body, a compatible phone or reader, and support in interpreting the data. Without that support, a stream of numbers can overwhelm rather than empower, which is why the trial’s structured follow-up is an important part of its design.
Clinicians also caution that monitors are a tool, not a treatment in themselves. The benefit comes from what patients and care teams do with the information, alongside established approaches to diet, activity, weight and medication described in guidance from organisations such as the World Health Organization.
What This Means for Patients
For adults with type 2 diabetes who are not on insulin, the study offers a concrete conversation to have with their doctor: whether a trial period with a sensor could reveal patterns worth acting on, even if long-term use is not immediately funded. Many patients discover specific meals, portion sizes or evening habits that drive their highest readings, insights that are difficult to obtain any other way.
It also underlines the value of combining technology with routine. The participants who benefited were not simply wearing a device; they were reviewing its information and adjusting behaviour, day after day.
A Shift in Diabetes Care
Diabetes care has been moving steadily from reactive testing toward continuous, data-informed management. This trial, the largest of its kind, gives that shift its strongest evidence yet for the much larger population of patients who do not use insulin.
If coverage and support follow the evidence, the small sensor on the arm could become as ordinary a part of type 2 diabetes care as the home blood-pressure cuff, and five extra hours a day in a healthy range could become an achievable standard rather than an exception.